In fiscal 2025, which ended Nov 30, 2025, Nurix Therapeutics, Inc. reported revenue of $84.0 million, up 54.0% from the year before. It recorded a net loss of $264.5 million. The operating loss came to $285.7 million, an operating margin of -340.2%. Diluted earnings per share were -$3.05. Over the twelve months ended Aug 31, 2026, revenue was $701.9 million and net income was $294.9 million. Across the 6 fiscal years shown, revenue grew from $17.8 million in fiscal 2020 to $84.0 million in fiscal 2025, about 36.3% a year.
USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.
| Line |
FY 2026
Aug 31, 2026
|
FY 2025
Nov 30, 2025
|
FY 2024
Nov 30, 2024
|
FY 2023
Nov 30, 2023
|
FY 2022
Nov 30, 2022
|
FY 2021
Nov 30, 2021
|
FY 2020
Nov 30, 2020
|
|---|---|---|---|---|---|---|---|
| Revenue |
702
+738.8%
|
84
+54.0%
|
55
-29.1%
|
77
+99.3%
|
39
+29.8%
|
30
+66.9%
|
18
|
| Research and development |
334
+10.9%
|
317
+43.0%
|
222
+17.2%
|
189
+2.5%
|
184
+58.5%
|
116
+75.1%
|
66
|
| Selling, general and administrative |
78
+57.0%
|
53
+14.8%
|
46
+7.1%
|
43
+12.9%
|
38
+21.8%
|
31
+91.3%
|
16
|
| Operating income |
290
+208.4%
|
-286
-34.1%
|
-213
-37.4%
|
-155
+15.7%
|
-184
-56.0%
|
-118
-81.4%
|
-65
|
| Pretax income |
308
+226.3%
|
-264
-36.4%
|
-193
-34.3%
|
-144
+20.2%
|
-180
-54.1%
|
-117
-83.6%
|
-64
|
| Income tax |
13
+1636.3%
|
1
+181.5%
|
0
|
—
|
0
-100.0%
|
0
+100.6%
|
-21
|
| Net income |
295
+220.5%
|
-264
-36.6%
|
-194
-34.5%
|
-144
+20.2%
|
-180
-53.9%
|
-117
-171.0%
|
-43
|
| Basic EPS |
2.76
+192.9%
|
-3.05
-5.9%
|
-2.88
-8.7%
|
-2.65
+28.6%
|
-3.71
|
—
|
—
|
| Diluted EPS |
2.69
+190.7%
|
-3.05
-5.9%
|
-2.88
-8.7%
|
-2.65
+28.6%
|
-3.71
|
—
|
—
|
| Weighted average shares, basic |
107
+29.6%
|
87
+29.1%
|
67
+23.5%
|
54
+11.8%
|
49
|
—
|
—
|
| Weighted average shares, diluted |
110
+32.8%
|
87
+29.1%
|
67
+23.5%
|
54
+11.8%
|
49
|
—
|
—
|
| Other measures | |||||||
| Depreciation and amortization |
9
-5.0%
|
9
-6.2%
|
9
+23.7%
|
8
+40.8%
|
5
+91.7%
|
3
+28.0%
|
2
|
| EBITDA |
298
+215.6%
|
-277
-35.9%
|
-204
-38.1%
|
-148
+17.4%
|
-179
-55.1%
|
-115
-83.3%
|
-63
|
| Margins | |||||||
| Operating margin |
41.27%
|
-340.16%
|
-390.52%
|
-201.41%
|
-476.01%
|
-396.26%
|
-364.66%
|
| Pretax margin |
43.91%
|
-314.00%
|
-354.36%
|
-186.98%
|
-466.93%
|
-393.49%
|
-357.90%
|
| Profit margin |
42.01%
|
-314.90%
|
-354.85%
|
-186.98%
|
-466.93%
|
-393.93%
|
-242.66%
|
| EBITDA margin |
42.51%
|
-329.75%
|
-373.44%
|
-191.63%
|
-462.16%
|
-386.88%
|
-352.43%
|
| Effective tax rate |
4.33%
|
—
|
—
|
—
|
—
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.
New to this? Read How to Read an Income Statement, With a Real Example.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NRIX (Nasdaq)
- Fiscal year ends
- November 30
- Incorporated in
- DE
- Headquarters
- Brisbane, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1549595
- Former names
- Nurix, Inc. (until Sep 18, 2015)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.